Keiji Sugiyama

Dr. Keiji Sugiyama

Department of Medical Oncology, Nagoya Medical Center

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2015 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
VBVincent Bauchau
Vincent Bauchau
LHLionel Van Holle
Lionel Van Holle
OMOlivia Mahaux
Olivia Mahaux
KHKatsiaryna Holl
Katsiaryna Holl
KSKeiji Sugiyama
Keiji Sugiyama
HBHubert Buyse
Hubert Buyse
Purpose: RotarixTM was launched in November 2011 in Japan to prevent rotavirus gastroenteritis. Some studies suggest that RotarixTM may have a temporal association with a risk of intussusception (IS). We assessed a possible association between IS and RotarixTM vaccination in Japan.Methods: All IS cases spontaneously reported post‐vaccination (Brighton collaboration levels 1, 2, and 3) were extracted from the GlaxoSmithKline spontaneous report database on the 11th of January 2013. Expected numbers of IS cases were estimated using the number of vaccine doses distributed and the Japanese incidence rate of IS stratified by month of age. The observed versus expected analysis considered the IS cases for each risk period (7 and 30 days post‐vaccination) and for each vaccine dose (two doses).Results: Before January 2013, approximately 601 000 RotarixTM doses were distributed in Japan. For a risk period of 7 days post‐dose 1 and post‐dose 2, 10 and five IS cases were observed, whereas 3.4 and 7.6 were expected, providing an observed‐to‐expected ratio of 2.96 (95% confidence interval [CI]: 1.42; 5.45) and 0.66 (95% CI: 0.21; 1.53), respectively. For a risk period of 30 days post‐dose 1 and post‐dose 2, 14 and eight cases were observed, whereas 14.5 and 32.7 were expected, providing an observed‐to‐expected ratio of 0.97 (95% CI: 0.53; 1.62) and 0.24 (95% CI: 0.11; 0.48), respectively.Conclusion: A statistically significant excess of IS cases was observed within 7 days post‐dose 1, but not post‐dose 2. These results are consistent with previous observations in large post‐marketing safety studies in other world regions. © 2015 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.

2 January 2023 in Nutrition and Cancer
Verified
Journal Article
Open access
KSKeiji Sugiyama
Keiji Sugiyama
KSKazuhiro Shiraishi
Kazuhiro Shiraishi
TMTakuya Motohashi
Takuya Motohashi
SOShinpei Onoda
Shinpei Onoda
MSMariko Sato
Mariko Sato
CKChiyoe Kitagawa
Chiyoe Kitagawa
Malnutrition and cachexia occur commonly in patients with advanced gastric cancer (AGC). This study elucidated the effect of nutritional support (NS) on survival outcomes among patients with AGC undergoing chemotherapy. We retrospectively evaluated new AGC cases at our institute between January 2015 and January 2021. Inclusion criteria were unresectable or recurrent chemotherapy-treated gastric adenocarcinoma, ECOG performance status (PS) 0–2, and adequate organ function. Time to treatment failure (TTF) and overall survival (OS) were evaluated, and univariate and multivariate analyses identified prognostic factors. A total of 103 eligible patients were separated into groups: 69 patients (67%) into NS and 34 (33%) into routine care (RC). The median follow-up time was 11.0 mo, (0.5–92). NS was offered to patients with poorer PS (p = 0.03), Glasgow prognostic score (GPS) positivity (p = 0.001), and high neutrophil-to-lymphocyte ratios (cut-off ≤ 3, p = 0.02). Median OS and TTF in the RC and NS groups were 11.6 and 10.4 mo, (p = 0.99) and 4.2 and 5.5 mo, (p = 0.07), respectively. Multivariate analyses identified NS (hazard ratio [HR] = 0.53, p = 0.01) and GPS positivity for TTF, and low body mass index (HR = 2.03, p = 0.007) and GPS positivity (HR = 2.25, p = 0.001) for OS as significant prognostic factors. Thus, NS with chemotherapy is a potentially effective intervention for AGC.

12 September 2020 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
KSKeiji Sugiyama
Keiji Sugiyama
KSKazuhiro Shiraishi
Kazuhiro Shiraishi
MSMariko Sato
Mariko Sato
RNRiko Nishibori
Riko Nishibori
KNKazuki Nozawa
Kazuki Nozawa
CKChiyoe Kitagawa
Chiyoe Kitagawa

29 October 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
KSKeiji Sugiyama
Keiji Sugiyama
NSNaureen Starling
Naureen Starling
ICIan Chau
Ian Chau
Growth differentiation factor 15 (GDF-15) is a stress-induced cytokine produced by tumour cells and peripheral cells. It is implicated in the development of cancer cachexia, a debilitating condition for which no effective pharmacological therapy currently exists. GDF-15 regulates appetite and metabolic processes through complex neural and hormonal networks. Furthermore, it has been implicated in chemotherapy-induced nausea and vomiting, representing a potential therapeutic target. GDF-15 negatively affects tumour immunity, suggesting that anti-GDF-15 therapy could potentially enhance immune responses and help overcome resistance to immunotherapy. Recently, early clinical trials have reported preliminary results of GDF-15-targeted therapies in alleviating cancer cachexia and potentially enhancing the efficacy of immunotherapy. This review aims to provide an overview of the role of GDF-15 in cancer cachexia, including the underlying neural mechanisms and their involvement in tumour immunity. This review also summarises recent clinical trial findings and discusses future perspectives on GDF-15-targeted therapy in oncology, offering important insights for future research.

17 January 2025 in Cancer Treatment Reviews
Verified
Journal Article
Open access
KSKeiji Sugiyama
Keiji Sugiyama
ICIan Chau
Ian Chau
Claudins (CLDNs) play a crucial and indispensable role as fundamental components within the structure of tight junctions. Due to the distinct and unique distribution pattern exhibited by CLDNs in both normal and malignant tissues, these proteins have garnered significant attention as pivotal targets for systemic anti-cancer therapy and as noteworthy diagnostic markers. This review provides a comprehensive and detailed elucidation of the fundamental understanding surrounding CLDNs, their intricate expression patterns, the potential role they play in cancer diagnosis and therapeutic potentials; all encapsulated within a succinct summary of the cutting-edge advancements and the information derived from various clinical trials.

25 February 2019 in In Vivo
Verified
Journal Article
Open access
PDF file
KSKeiji Sugiyama
Keiji Sugiyama
AIAkari Iwakoshi
Akari Iwakoshi
MSMariko Satoh
Mariko Satoh
KSKazuhiro Shiraishi
Kazuhiro Shiraishi
KNKazuki Nozawa
Kazuki Nozawa
HSHideo Saka
Hideo Saka
Background: There are no established guidelines for the management of apocrine carcinomas of the breast; they are treated as a non-specific type of breast cancer. Case Report: We report on the case of a 40-year-old man who developed primary mediastinal apocrine carcinoma overexpressing human epidermal growth factor-2 (HER2). The patient initially underwent complete resection of a mediastinal mature teratoma with a focal apocrine carcinoma component. Two years after surgery, relapse was detected in multiple mediastinal lymph nodes. He received induction chemotherapy including docetaxel, trastuzumab, and pertuzumab; consolidative concurrent chemoradiation was added after six cycles. A complete response was confirmed using computed tomography following this multimodal therapy. After chemoradiation, adjuvant trastuzumab and pertuzumab were administered for 1 year and the patient has since had no evidence of progressive disease. Conclusion: A multi-modal regimen that includes an anti-HER2 agent appears to be a promising treatment for patients with HER2-positive extramammary apocrine carcinoma.